Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Mini Rev Med Chem ; 8(6): 619-27, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18537717

RESUMEN

Endothelial Lipase (EL) is a newly identified member of the triacylglycerol lipase family. Recent studies suggested that EL may be an important determinant of HDL-metabolism and inflammation acting at the level of the vessel wall. The aim of this review is to summarize important facts derived from experimental approaches and from epidemiologic human studies to provide a comprehensive view on the role of EL in inflammation and atherogenesis as well as target for potential pharmaceutical interventions.


Asunto(s)
Aterosclerosis/fisiopatología , Endotelio/enzimología , Inflamación/fisiopatología , Lipasa/fisiología , Lipoproteínas HDL/metabolismo , Animales , Humanos , Factores de Riesgo
2.
Pulm Pharmacol Ther ; 15(4): 369-74, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12220942

RESUMEN

Formoterol inhaled via Turbuhaler (Oxis) or Aerolizer (Foradil) produces fast and long-lasting bronchodilation in asthmatic patients. While formoterol Turbuhaler provides sustained efficacy for > or =12h at a metered dose of 6 microg (delivered dose 4.5 microg), the recommended metered dose for formoterol Aerolizer is 12 microg (delivered dose unknown). This difference may be attributable to improved lung deposition with the Turbuhaler. This open, randomised, crossover study compared the effects of a single metered dose of formoterol Turbuhaler 6 microg and formoterol Aerolizer 12 microg in 16 patients with stable moderate-to-severe asthma. Pulmonary function, assessed by measuring specific airway conductance (sGaw), was determined at intervals of < or =8h post-inhalation of each drug on separate study days. Both inhalers increased sGaw at all time points. There were no significant differences between the two formulations in onset of activity, maximum effect, duration of effect or area under the response curve. Furthermore, both treatments were well tolerated with no differences in adverse events, blood pressure or heart rate; thus the formoterol Turbuhaler may, therefore, have an improved therapeutic index. This pilot study indicates that the same clinical effect can be achieved with half the metered dose (6 microg) of formoterol Turbuhaler compared with formoterol Aerolizer (12 microg).


Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/administración & dosificación , Etanolaminas/administración & dosificación , Administración por Inhalación , Adulto , Anciano , Resistencia de las Vías Respiratorias/efectos de los fármacos , Asma/fisiopatología , Broncodilatadores/uso terapéutico , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Etanolaminas/uso terapéutico , Femenino , Fumarato de Formoterol , Humanos , Masculino , Persona de Mediana Edad , Nebulizadores y Vaporizadores , Evaluación de Resultado en la Atención de Salud , Proyectos Piloto , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA